Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and sign an Investigational Review Board (IRB)-approved written informed consent and privacy language (e.g., Health Insurance Portability and Accountability Act (HIPAA) authorization) as per national regulations before any study-related procedures are performed.~* Must have a diagnosis of idiopathic PD.~* Adult male or female 18 to 78 years of age, inclusive.~* Currently using APOKYN, per the Package Insert, for at least 4 weeks before Baseline Assessment Visit(s).~* Currently using carbidopa/levodopa therapy at a steady maintenance dose, representing a stable treatment regimen in the opinion of the Investigator, for at least 4 weeks before Baseline Assessment Visit(s).~* Able to walk 50 feet independently (cane permissible) at the Baseline Assessment Visit.~* Meet all of the following parameters to demonstrate an optimal response to APOKYN at the APOKYN Response Verification Visit: must be on in the opinion of the subject and investigator within 20 minutes after the APOKYN injection; and have a motor state improvement of \>25% per the Movement Disorder Society (MDS)-UPDRS Motor Score (Part III), within 20 minutes after the APOKYN injection, as compared to pre-injection.~* Willing and able to comply with scheduled visits, treatment plan, other study-related procedures, and have available caregiver to provide transportation to clinic visits as needed.~Exclusion Criteria:~* Received PT targeting Parkinson's disease within 6 months before Baseline Assessment Visit(s).~* Received any investigational (i.e., unapproved) drug product within the last 30 days (or 5 half-lives, whichever is longer) before the Baseline Assessment Visit(s).~* Currently taking, or likely to need to take at any time during the course of the study, any 5HT3 antagonist (i.e., ondansetron, granisetron, dolasetron, palonosetron, alosetron).~* Currently on or likely to transition to the DUOPA (carbidopa and levodopa enteral suspension) during the course of the study.~* Has orthostatic hypotension (defined as \>30 mmHg decrease in systolic blood pressure or \>15 mmHg decrease in diastolic blood pressure within 2 minutes of standing from a supine position) at the Baseline Assessment Visit(s), or within 20 minutes following APOKYN injection at the APOKYN Verification Visit.~* Has a score of 24 or higher on the Modified Physical Performance Test (M-PPT).~* Has a score of 80% or higher on the Activities-specific Balance Confidence Scale (ABC).~* Has any significant current medical disorder, physical, or mental condition that would, in the Investigator's opinion, represent a hazard to the subject or prevent the subject from completing the study.~* Subjects with dementia, in the Investigator's opinion, or subjects with a Montreal Cognitive Assessment (MoCA) \<18.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Apokyn treatment before physical therapy (Type: ACTIVE_COMPARATOR): APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
- Apokyn treatment withheld before physical therapy (Type: OTHER): APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).